Comprehensive proteomics, bioinformatics, and targeted RNA assays show disruption in signaling pathways related to protein translation control and tumorigenesis, among others, with central control stemming from significantly increased MYC and decreased TP53 in GBM-EV stimulated astrocytes. The gene discussed is TP53; the disease is glioblastoma.